Oryzon Genomics - KOL event puts near-term catalysts in the spotlight
At Oryzon’s recent key opinion leader (KOL) event, management elaborated on the near-term clinical catalysts for its lead assets iadademstat, in...
261 Views
Oryzon Genomics - Progress in oncology and CNS in FY22
Oryzon Genomics has presented headline FY22 financial results, which reflect continued progress on its clinical activities for key assets...
331 Views
Oryzon Genomics - First Phase II patient enrolled is clinical milestone
Oryzon Genomics has announced that it has enrolled the first patient into its collaborative Phase II trial investigating the use of its lead LSD1...
253 Views
Oryzon Genomics - Lead asset granted expansion into combo therapies
Oryzon Genomics has announced that it has been awarded an EU grant to initiate a project to investigate the company’s lead clinical oncology asset,...
745 Views
Oryzon Genomics - Positive ALICE readouts pave way in AML
Oryzon Genomics has presented the top-line results of its Phase IIa ALICE trial investigating its lead oncology LSD1 inhibitor iadademstat in...
757 Views